|
Re: new herceptin targeted immunoliposomal drug being developed--works vs. herceptin
the fact it was published in an american chemical society journal makes me worry it might not be starting clinical trials too soon. Not everyone reads so widely in the literature, so this may get missed ... It depends if they get to give a paper or present a poster at a conference, have good connections to those who could develop it further etc.
Had Genentech done the work, I would think they might work on it as an alternative to TDM1 and things might move ahead faster.
If I see someone presenting on something similar @ ASCO I will bring it to their attention, so maybe they can collaborate and move things forward faster.
|